The Food and Drug Administration granted approval to Eli Lilly's Alzheimer's drug ... compete with Eisai and Biogen's Leqembi, which the FDA approved last year. Catch up quick: In June, a key ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

Fosgonimeton, aimed at protecting neurons, failed to do better than placebo at slowing cognitive decline in patients with ...

New research reveals a potential breakthrough in Alzheimer’s treatment, showing that the drug troriluzole can reverse memory ...

Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients ...

As quantitative data replaced qualitative descriptions in the ads, and as information about severe adverse effects was ...

Gwendolyn Wu Biogen is teaming up with two diagnostics developers to identify biological markers for Alzheimer’s ... Reading Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales ...

In June, the FDA’s advisory committee delivered a favorable verdict on the Eli Lilly And Co’s (NYSE:LLY) Alzheimer’s treatment donanemab, declaring its benefits to surpass the associated risks. “We ...

Eli Lilly received FDA breakthrough status for its donanemab Alzheimer's drug, speeding the agency's review of the product. The shares are higher. Eli Lilly (LLY) shares rose Thursday after ...